Anti-human Immunodeficiency Virus-1 Antibody Titers in Injection Drug Users Compared to Sexually Infected Individuals

Memorias do Instituto Oswaldo Cruz

Volumn 98, Issue 2, 2003, Pages 209-212

  Bongertz, Vera ^a   Ouverney, Elaine Priscilla ^a   Teixeira, Sylvia L M ^a   Silva de Jesus, Carlos ^a   Hacker, Mariana A ^a   Morgado, Mariza G ^a   Bastos, Francisco I ^a   Galvão Castro, Bernardo ^b   Ferraro, Geraldo A ^b   Mello, Marco A ^b   Brigido, Luis ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Ctro Informacoes Cie Tecn Fiocruz ^*

Author keywords

Antibodies; Human immunodeficiency virus 1; Injection drug users

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PEPTIDE; UNCLASSIFIED DRUG; V3 PEPTIDE; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305 321); HIV ENVELOPE PROTEIN GP120 (305-321); PEPTIDE FRAGMENT;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABUSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOREACTIVITY; PLASMA; SEXUALLY TRANSMITTED DISEASE; COMPARATIVE STUDY; CROSS REACTION; DISEASE COURSE; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; PROGNOSIS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

CROSS REACTIONS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; PEPTIDE FRAGMENTS; PROGNOSIS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0038605249     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762003000200007     Document Type: Article

References (24)

1. Alberti S, Hacker M, Custodio Miguel J, Oliveira ML, Bastos FI 2001. Can viral hepatitis be kept under control among injection drug users? Lessons from the field, in Rio de Janeiro, Brazil. Virus Rev Res 6 (Suppl. 1): 109.
2. Barin F, Lahbabi Y, Buzelay L, Lejeune B, Baillou-Beaufils A, Denis F, Mathiot C, M'Boup S, Vithayasai V, Dietrich U, Goudeau A 1996. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV-1 serological subtyping. AIDS Res Hum Retrov 12: 1279-1289.
3. Bastos FI, Telles PR, Hacker M 2001. Uma década de pesquisas sobre usuários de drogas injetáveis & HIV/AIDS no Rio de Janeiro. Parte I: "Rumo a uma epidemia sob controle?" In A Contribuição dos Estudos Multicêntricos Frente à Epidemia de HIV/AIDS entre UDI no Brasil (Série Avaliação 8), Ministério da Saúde, Brasilia, p. 49-78.
4. Bongertz V, Guimarães ML, Soares-da-Costa MFG, Velosodos-Santos VG, The HEC/Fiocruz AIDS Clin Res Group, Bastos FI, Telles PR, Morgado MG 1999. Anti-HIV-1 seroreactivity in distinct transmission risk groups. J Clin Virol 12: 37-42.
5. Brown L, Westby M, Souberbielle BE, Szawlowski PW, Kemp G, Hay P, Dalgleish AG 1997. Optimization of a peptide-based indirect ELISA for the detection of antibody in the serum of HIV-1 seropositive patients. J Immunol Meth 200: 79-88.
6. Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C 1987. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 84: 4249-4253.
7. Delwart EL, Shpaer EG, Louwagie J, McCutchan FE, Grez M, Rübsamen-Waigmann H, Mullins JI 1993. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 262: 1257-1261.
8. Gaines H, von Sydow M, Pehrson PO, Lundbegh P 1988. Clinical picture of primary HIV infection presenting as a glandular-fever-like illness. BMJ 297: 1363-1368.
9. Hendricks JCM, Satten GA, van Ameijden ECJ, van Druten HAM, Coutinho RA, van Griensven GJP 1998. The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis. AIDS 12: 1537-1544.
10. Jansson M, Wahren B, Albert J, Scarlatti G, Franzen L, Kattaaha R, Katabira E, Mubiro F, Wigzell H, Rossi P 1994. Peptide serology for analysis of intra-and interindividual variation in the V3 domain. AIDS 8: 413-421.
11. Liao HX, Etemad-Moghadam B, Montefiori DC, Sun Y, Sodroski J, Scearce RM, Doms RW, Thomasch JR, Robinson S, Letvin NL, Haynes BF 2000. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains. J Virol 74: 254-63.
12. Lukashov VV, Goudsmit J 1997. Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution? J Virol 71: 2023-2030.
13. Morgado M, Guimaraes M, Galvão-Castro B 2002. HIV-1 polymorphism: a challenge for vaccine development - A review. Mem Inst Oswaldo Cruz 97: 143-150.
14. Moore JP, Burton DR 1999. HIV-1 neutralizing antibodies: How full is the bottle? Nature Med 5: 142-144.
15. Pehrson PO, Lindbäck S, Lidman C, Gaines H, Giesecke J 1997. Longer survival after HIV infection for injecting drug users than for homosexual men: implications for immunology. AIDS 11: 1007-1012.
16. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AC, Montefiori DC 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-termnonprogressive infection. J Infect Dis 176: 924-932.
17. Prins M, Aguado IH, Brettle RP, Robertson JR, Broers B, Carré N, Goldberg DJ, Zangerle R, Coutinho RA, van den Hoek A 1997. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 11: 1747-1756.
18. Selwyn PA, Hartel D, Wasserman W, Drucker E 1989. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. Am J Public Health 79: 1358-1362.
19. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W 1993. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7: 1159-1166.
20. Sinicco A, Fora R, Sciandra M, Lucchini A, Caramello P, Gioannini P 1993. Risk of developing AIDS after primary acute HIV-1 infection. J Acquir Immune Defic Synd 6: 575-581.
21. Teixeira SLM, Bastos FI, Telles PR, Derrico M, Morgado MG 2001a. Low seroprevalence of HIV-1 infection and detection of B-F HIV-1 subtypes by gag/env-HMA among injection drug users (IDUs) of Rio de Janeiro, Brazil. J Inf Dis 5: S10 (AO-28).
22. Teixeira SLM, Bastos FI, Telles PR, Hacker M, Morgado MG 2001b. HIV-1 gag, env and protease polymorphism in HIV-1 positive injection drug users (IDUs) of Rio de Janeiro, Brazil. J Braz Soc Virol Virus Rev Res 6 (Suppl. 1): 676 (RV20).
23. van Haastrecht HJ, van Ameijden EJ, van den Hoek JA, Mientjes GH, Bax JS, Coutinho RA 1996. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 143: 380-391.
24. Wetli CV, Noto TA, Fernandez-Carol A 1974. Immunologic abnormalities in heroin addiction. South Med J 67: 193-197.